Abilify in adolescents

Use of Abilify (aripiprazole) in adolescents aged 15 years and above with schizophrenia has been approved. The recommended dose in this population is 10mg daily. Use of the drug to treat manic episodes in bipolar disorder remains not recommended under 18 years.

View Abilify drug record

Further information: Otsuka


To sign up for the MIMS monthly news update, register at www.mims.co.uk/bulletins.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

'Innovative' heart failure treatment recommended by NICE

'Innovative' heart failure treatment recommended by NICE

Dapagliflozin (Forxiga), the first SGLT2 inhibitor...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Pregabalin linked to severe respiratory depression in absence of opioids

Pregabalin linked to severe respiratory depression in absence of opioids

The MHRA advises prescribers to consider adjustment...